Report cover image

Blood Cancer Drugs Global Market Report 2022

Publisher The Business Research Company
Published Mar 15, 2022
Length 175 Pages
SKU # BRC17029295

Description

Blood Cancer Drugs Global Market Report 2022

Blood Cancer Drugs Global Market Report 2022 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the global blood cancer drugs market as it emerges from the Covid 19 shut down.

Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order.
Description:

Where is the largest and fastest growing market for the blood cancer drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Blood Cancer Drugs Market Global Report from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The Market Characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the impact of the Covid 19 virus and forecasting its recovery.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the impact and recovery trajectory of Covid 19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope

Markets Covered: 1) By Blood Cancer Type: Leukemia; Lymphoma

2) By Drugs: Rituaxan/Mabthera (Rituximab); Gleevac/Glivec (Imatinib); Revlimid (Lenalidomide); Velcade (Bortezomib); Tasigna (Nilotinib); Pomalyst (Pomalidomide); Vidaza (Azacitidine); Kyprolis (Carfilzomib); Adcetris (Brentuximab Vedotin); Others

3) By Treatment Approaches: Key Findings; Chemotherapeutic; mAbs/Targeted Therapies; Immunotherapeutic

Companies Mentioned: Amgen Inc.; AstraZeneca PLC.; Bayer AG; Celgene Corporation; Eli Lilly

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast.

Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Please Note: Report will be updated with the latest data and delivered to you within 3-5 working days of order.

Table of Contents

175 Pages
1. Executive Summary
2. Blood Cancer Drugs Market Characteristics
3. Blood Cancer Drugs Market Trends And Strategies
4. Impact Of COVID-19 On Blood Cancer Drugs
5. Blood Cancer Drugs Market Size And Growth
5.1. Global Blood Cancer Drugs Historic Market, 2016-2021, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Blood Cancer Drugs Forecast Market, 2021-2026F, 2031F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market
6. Blood Cancer Drugs Market Segmentation
6.1. Global Blood Cancer Drugs Market, Segmentation By Blood Cancer Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
Leukemia
Lymphoma
6.2. Global Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
Rituaxan/Mabthera (Rituximab)
Gleevac/Glivec (Imatinib)
Revlimid (Lenalidomide)
Velcade (Bortezomib)
Tasigna (Nilotinib)
Pomalyst (Pomalidomide)
Vidaza (Azacitidine)
Kyprolis (Carfilzomib)
Adcetris (Brentuximab Vedotin)
Others
6.3. Global Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
Key Findings
Chemotherapeutic
mAbs/Targeted Therapies
Immunotherapeutic
7. Blood Cancer Drugs Market Regional And Country Analysis
7.1. Global Blood Cancer Drugs Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
7.2. Global Blood Cancer Drugs Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
8. Asia-Pacific Blood Cancer Drugs Market
8.1. Asia-Pacific Blood Cancer Drugs Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
8.3. Asia-Pacific Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
9. China Blood Cancer Drugs Market
9.1. China Blood Cancer Drugs Market Overview
9.2. China Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion
9.3. China Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion
10. India Blood Cancer Drugs Market
10.1. India Blood Cancer Drugs Market, Segmentation By Blood Cancer Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
10.2. India Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
11. Japan Blood Cancer Drugs Market
11.1. Japan Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
11.2. Japan Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
12. Australia Blood Cancer Drugs Market
12.1. Australia Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
12.2. Australia Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
13. Indonesia Blood Cancer Drugs Market
13.1. Indonesia Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
13.2. Indonesia Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
14. South Korea Blood Cancer Drugs Market
14.1. South Korea Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
14.2. South Korea Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
15. Western Europe Blood Cancer Drugs Market
15.1. Western Europe Blood Cancer Drugs Market Overview
15.2. Western Europe Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
15.3. Western Europe Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
16. UK Blood Cancer Drugs Market
16.1. UK Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
16.2. UK Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
17. Germany Blood Cancer Drugs Market
17.1. Germany Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
17.2. Germany Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
18. France Blood Cancer Drugs Market
18.4. France Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
18.5. France Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
19. Eastern Europe Blood Cancer Drugs Market
19.1. Eastern Europe Blood Cancer Drugs Market Overview
19.2. Eastern Europe Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
19.3. Eastern Europe Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
20. Russia Blood Cancer Drugs Market
20.1. Russia Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
20.2. Russia Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
21. North America Blood Cancer Drugs Market
21.1. North America Blood Cancer Drugs Market Overview
21.2. North America Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
21.3. North America Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
22. USA Blood Cancer Drugs Market
22.1. USA Blood Cancer Drugs Market Overview
22.2. USA Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
22.3. USA Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
23. South America Blood Cancer Drugs Market
23.1. South America Blood Cancer Drugs Market Overview
23.2. South America Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
23.3. South America Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
24. Brazil Blood Cancer Drugs Market
24.1. Brazil Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
24.2. Brazil Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
25. Middle East Blood Cancer Drugs Market
25.1. Middle East Blood Cancer Drugs Market Overview
25.2. Middle East Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
25.3. Middle East Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
26. Africa Blood Cancer Drugs Market
26.1. Africa Blood Cancer Drugs Market Overview
26.2. Africa Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
26.3. Africa Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
27. Blood Cancer Drugs Market Competitive Landscape And Company Profiles
27.1. Blood Cancer Drugs Market Competitive Landscape
27.2. Blood Cancer Drugs Market Company Profiles
27.2.1. Amgen Inc.
27.2.1.1. Overview
27.2.1.2. Products and Services
27.2.1.3. Strategy
27.2.1.4. Financial Performance
27.2.2. AstraZeneca PLC
27.2.2.1. Overview
27.2.2.2. Products and Services
27.2.2.3. Strategy
27.2.2.4. Financial Performance
27.2.3. Bayer AG
27.2.3.1. Overview
27.2.3.2. Products and Services
27.2.3.3. Strategy
27.2.3.4. Financial Performance
27.2.4. Celgene Corporation
27.2.4.1. Overview
27.2.4.2. Products and Services
27.2.4.3. Strategy
27.2.4.4. Financial Performance
27.2.5. Eli Lilly
27.2.5.1. Overview
27.2.5.2. Products and Services
27.2.5.3. Strategy
27.2.5.4. Financial Performance
28. Blood Cancer Drugs Pipeline Analysis
29. Key Mergers And Acquisitions In The Blood Cancer Drugs Market
30. Blood Cancer Drugs Market Future Outlook and Potential Analysis
31. Appendix
31.1. Abbreviations
31.2. Currencies
31.3. Research Inquiries
31.4. The Business Research Company
31.5. Copyright And Disclaimer

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us